Current medical treatment for tuberculosisBMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7388.550/a (Published 08 March 2003) Cite this as: BMJ 2003;326:550
Aspects of chemotherapy and management need clarifying
- Lawrence P Ormerod, consultant respiratory physician (email@example.com),
- Ian A Campbell, consultant respiratory physician,
- Peter D O Davies, consultant respiratory physician
- Blackburn Royal Infirmary, Blackburn BB2 3LR
- Llandough Hospital, Cardiff CF74 2XX
- Aintree University Hospital, Liverpool L9 7AL For the Joint Tuberculosis Committee of the British Thoracic Society
- Department of Health Services Research, Norwegian Directorate for Health and Social Affairs, PO Box 8054, N-0031 Oslo, Norway
- National Jewish Medical and Research Center, 1400 Jackson Street, Denver, CO 80206, USA
- Mayday Hospital, Croydon CR7 7YE
- St George's Hospital, London SW17 0QT
EDITOR—We take issue with some of the comments made by Chan and Iseman in their clinical review of current medical treatment for tuberculosis.1 These points have already been covered in the evidence based guidelines on both the chemotherapy and management and the control and prevention of tuberculosis by the Joint Tuberculosis Committee of the British Thoracic Society, but we believe that they bear restatement. 2 3
Supplementation with pyridoxine (up to 50 mg/day) as routine—Peripheral neuropathy from isoniazid is very uncommon. Pyridoxine is appropriate for patients at increased risk of peripheral neuropathy.2 However, pyridoxine antagonises isoniazid on a milligram for milligram basis. Studies have shown that only 6 mg/day prevents peripheral neuropathy, so only 10 mg (the smallest tablet size available) should be used, if indicated.
Routine liver function monitoring—Detailed advice on liver function monitoring has been given and is incorporated in the 1998 code of practice, 2 4 but regular liver function measurements are not required in patients with normal pretreatment liver function, unless symptoms, in an informed patient, suggest hepatic upset.
Monthly visual acuity checks of patients taking ethambutol—Ocular toxicity is extremely rare in patients with normal visual acuity (Snellen chart) and renal function who are taking an ethambutol dose of 15 mg/kg, and there is no evidence that regular ocular checks prevent events.5 …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial